- Home
- IMCR vs DAC Comparison
IMCR vs DAC Comparison
Compare IMCR & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- DAC
- Stock Information
- Founded
- IMCR 2008
- DAC 1972
- Country
- IMCR United Kingdom
- DAC Greece
- Employees
- IMCR N/A
- DAC N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- DAC Marine Transportation
- Sector
- IMCR Health Care
- DAC Consumer Discretionary
- Exchange
- IMCR Nasdaq
- DAC Nasdaq
- Market Cap
- IMCR 1.5B
- DAC 1.4B
- IPO Year
- IMCR 2021
- DAC 2006
- Fundamental
- Price
- IMCR $30.42
- DAC $80.74
- Analyst Decision
- IMCR Buy
- DAC Strong Buy
- Analyst Count
- IMCR 11
- DAC 1
- Target Price
- IMCR $59.44
- DAC $105.00
- AVG Volume (30 Days)
- IMCR 377.5K
- DAC 113.4K
- Earning Date
- IMCR 05-12-2025
- DAC 05-27-2025
- Dividend Yield
- IMCR N/A
- DAC 4.23%
- EPS Growth
- IMCR N/A
- DAC N/A
- EPS
- IMCR N/A
- DAC 26.05
- Revenue
- IMCR $310,202,000.00
- DAC $1,014,110,000.00
- Revenue This Year
- IMCR $20.26
- DAC $4.23
- Revenue Next Year
- IMCR $8.49
- DAC N/A
- P/E Ratio
- IMCR N/A
- DAC $3.07
- Revenue Growth
- IMCR 24.36
- DAC 4.16
- 52 Week Low
- IMCR $23.15
- DAC $65.40
- 52 Week High
- IMCR $62.74
- DAC $98.25
- Technical
- Relative Strength Index (RSI)
- IMCR 57.69
- DAC 56.01
- Support Level
- IMCR $27.55
- DAC $75.11
- Resistance Level
- IMCR $31.20
- DAC $81.53
- Average True Range (ATR)
- IMCR 1.50
- DAC 2.08
- MACD
- IMCR 0.37
- DAC 0.84
- Stochastic Oscillator
- IMCR 83.90
- DAC 87.47
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.